Bridging clinical medicine, computational science, and genomics to develop transparent AI-driven tools for personalized oncology
The rapid evolution of artificial intelligence is transforming the way clinicians approach cancer diagnosis, prognosis, and treatment planning. As precision oncology increasingly depends on integrating clinical observations with genomic, molecular, and pharmacological information, physicians face the challenge of interpreting complex data while making timely, evidence-based decisions.
Artificial intelligence offers powerful analytical capabilities, but successful implementation in healthcare requires more than accurate predictions. Clinical adoption depends on systems that provide transparent, interpretable recommendations, allowing physicians to understand the reasoning behind algorithmic outputs and incorporate them into patient care. This emphasis on explainable artificial intelligence has become central to the development of next-generation decision-support technologies in oncology.
Among the physician-scientists working at the intersection of medicine and computational science is Dr. Latha Kiran Krishna Rajendran, whose research combines clinical medicine, pharmacogenomics, artificial intelligence, and translational oncology. Her work is directed toward developing clinically interpretable computational models that assist physicians in making individualized, evidence-informed decisions across multiple stages of cancer management.
Clinical Challenges Driving Computational Innovation
Many unanswered questions in oncology originate in everyday clinical practice. Patients with apparently similar tumour characteristics frequently experience different disease trajectories, respond differently to identical therapies, and demonstrate considerable variation in survival outcomes. These differences highlight the need for methods capable of integrating diverse sources of biomedical information.
Dr. Rajendran’s research addresses these challenges by combining clinical characteristics, genomic data, molecular biology, and computational modelling to generate clinically meaningful decision-support systems. Her experience across primary care, emergency medicine, preventive healthcare, chronic disease management, maternal and child health, geriatric medicine, and community health provides a broad clinical perspective that informs the development of practical artificial intelligence applications. Throughout this work, AI is positioned as a tool that strengthens physician judgement rather than replacing clinical expertise.
Building Transparent Artificial Intelligence for Oncology
As artificial intelligence becomes more deeply integrated into healthcare, interpretability has emerged as a critical requirement alongside predictive performance. Clinicians must be able to evaluate why an algorithm reaches a particular conclusion before its recommendations can be incorporated into routine clinical decision-making.
This principle is reflected across several of Dr. Rajendran’s investigations.
In patients with resected Stage III non-small cell lung cancer, predicting long-term survival and selecting optimal postoperative therapy remain difficult because individuals with comparable pathological staging often experience substantially different outcomes. To address this challenge, her research developed a deep learning framework that combines clinicopathological variables to improve individualized survival prediction and support personalized adjuvant treatment planning.
Another investigation focused on early mortality prediction in acute myeloid leukemia. Instead of relying exclusively on opaque “black-box” machine learning models, the research introduced an interpretable decision-tree framework that enables clinicians to identify the factors influencing individual predictions, facilitating AI-assisted clinical decision-making.
Additional research explores pharmacogenomics and the molecular mechanisms underlying therapeutic response. Through analysis of large-scale cancer datasets, these studies investigate biomarkers and biological pathways that may explain why genetically distinct tumours respond differently to similar treatments, contributing to more precise therapeutic selection.
Earlier cancer detection represents another important area of investigation. A systematic review evaluated symptom-based machine learning models for cancer detection, examining methodological quality and their potential for implementation in routine clinical practice.
In another study, Dr. Rajendran developed a machine learning-based clinical decision-support framework to stratify patients according to potential risks associated with Bevacizumab therapy. By identifying individuals who may benefit from additional evaluation before treatment, the framework illustrates how predictive analytics can support individualized therapeutic planning.
Although these investigations span different cancer types and clinical questions, they share a common objective: developing artificial intelligence systems that combine predictive accuracy with clinical transparency and practical usefulness. Collectively, they demonstrate a translational research approach in which computational innovation is directed toward solving clinically relevant problems.
Translating Research into Emerging Healthcare Technologies
A central objective of translational medicine is to bridge the gap between scientific discovery and clinical application. In precision oncology, this increasingly involves combining advances in computational biology, artificial intelligence, and molecular medicine to create technologies with the potential to improve diagnosis, treatment selection, and disease prediction.
In addition to her scientific publications, Dr. Rajendran has pursued technological innovation through intellectual property development. Her portfolio of published Indian utility patents and a United States utility patent application reflects an approach that extends computational research beyond academic investigation toward technologies with potential clinical relevance. These innovations encompass artificial intelligence-enabled immunotherapy, therapeutic target discovery, precision drug delivery, predictive disease modelling, and multi-omics analysis.
Among these developments is a United States utility patent application describing a Predictive Invisible Cancer Emergence and Bio-Digital Twin System. The proposed technology investigates computational representations of biological systems capable of simulating disease evolution and predicting therapeutic response before clinical intervention. Although bio-digital twin technology remains an emerging area of biomedical research, it has potential applications in predictive diagnostics, treatment optimization, and personalized healthcare.
Connecting Clinical Medicine, Public Health, and Biomedical Research
A defining characteristic of Dr. Rajendran’s research is the integration of clinical practice, biomedical investigation, public health, and technological innovation. Rather than addressing isolated scientific questions, her work emphasizes the application of computational methods to challenges encountered in routine patient care.
Across multiple investigations, recurring themes include early identification of patients at elevated risk, prediction of therapeutic response, individualized survival assessment, and the development of transparent clinical decision-support systems. This translational perspective reflects a commitment to ensuring that advances in computational science remain aligned with practical healthcare delivery.
Advancing Scientific Scholarship
Beyond conducting original research, Dr. Rajendran contributes to the broader scientific community through peer review for international journals and conference proceedings covering oncology, artificial intelligence, computational medicine, and translational science.
Her scholarly activities also include the authorship of scientific books focused on immunotherapy, cancer nanomedicine, theranostics, genomic therapeutics, and precision oncology. These publications contribute to the dissemination of emerging biomedical knowledge among clinicians, researchers, and students.
Additional academic engagement includes invited lectures, keynote presentations, conference session chair responsibilities, and participation in innovation competitions evaluating emerging healthcare technologies and AI-enabled medical solutions.
Foundations in Public Health
Before expanding her research in computational oncology, Dr. Latha Kiran Krishna Rajendran served as a Medical Officer at an Urban Public Health Centre under BBMP, managed by Karuna Trust in Bengaluru.
During the COVID-19 pandemic, she participated in vaccination programmes, infectious disease surveillance, diagnostic services, and community healthcare initiatives. These experiences strengthened her appreciation for evidence-based medicine, preventive healthcare, and scalable healthcare strategies. The perspectives gained through public health practice continue to influence her work in translational medicine and precision oncology.
The Evolving Role of Explainable Artificial Intelligence
As precision oncology continues to advance, artificial intelligence, genomics, and computational medicine are expected to become increasingly integrated into routine clinical practice. Their long-term value will depend not only on improvements in computational performance but also on the development of systems that physicians can interpret, evaluate, and confidently incorporate into evidence-based clinical decision-making.
The growing emphasis on explainable artificial intelligence reflects a broader shift toward technologies that support, rather than replace, clinical expertise. By combining computational innovation with clinical insight, these approaches have the potential to strengthen individualized treatment planning, improve patient stratification, and enhance therapeutic decision-making across oncology.
Dr. Latha Kiran Krishna Rajendran’s research reflects this evolving direction in modern cancer care. Through the integration of artificial intelligence, genomics, pharmacogenomics, and clinical medicine, her work contributes to the ongoing development of transparent, clinically meaningful, and translational technologies designed to address important challenges in precision oncology and support more personalized, evidence-informed patient care.
